Influence of primary tumor location and resection on survival in metastatic colorectal cancer

Table 2 Univariate Cox model

		HR	95%CI	P value
Age	n = 466			0.0714
> 65 yr vs ≤ 65 yr		1.209	[0.984-1.485]
Gender	n = 466			0.3701
Female vs male		1.099	[0.894-1.350]
Tumor location	n = 466			0.0022
Rectum vs left colon + sigmoid		1.019	[0.767-1.355]
Right colon + transverse colon vs Left colon + sigmoid		1.464	[1.16-1.841]
Number of metastatic sites	n = 466			0.0035
2 vs 1		1.219	[0.965-1.539]
> 2 vs 1		1.749	[1.245-2.455]
Number of metastatic sites	n = 466			0.0084
≥ 2 vs 1		1.328	[1.076-1.641]
Liver metastases	n = 464			0.8836
Yes vs No		1.020	[0.782-1.330]
Lung metastases	n = 463			0.6435
Yes vs No		1.057	[0.835-1.338]
Peritoneum metastases	n = 463			0.0619
Yes vs No		1.260	[0.989-1.606]
Other metastases	n = 462			0.0114
Yes vs No		1.377	[1.075-1.765]
KRAS mutation	n = 356			0.0696
Yes vs No		1.256	[0.982-1.606]
BRAF mutation	n = 294			< 0.0001
Yes vs No		2.276	[1.511-3.429]
CEA	n = 366			< 0.0001
> 200 vs ≤ 200		1.654	[1.290-2.120]
LDH	n = 329			< 0.0001
> 254 vs ≤ 254		2.022	[1.574-2.596]
Leukocytes > 10000	n = 361			0.0016
Yes vs No		1.506	[1.168-1.941]
Alkaline phosphatase > 300	n = 335			< 0.0001
Yes vs No		2.272	[1.713-3.014]
PTR	n = 466			< 0.0001
Yes vs No		0.313	[0.250-0.392]
Oxaliplatin	n = 466			< 0.0001
Yes vs No		0.361	[0.248-0.524]
Irinotecan	n = 465			0.112
Yes vs No		0.807	[0.619-1.051]
5 FU or Capecitabine	n = 466			0.2869
Yes vs No		0.539	[0.173-1.682]
Bevacizumab	n = 463			0.0117
Yes vs No		0.750	[0.599-0.938]
EGFR inhibitors	n = 464			0.0129
Yes vs No		0.769	[0.625-0.946]
1rst line chemotherapy regimen	n = 462			0.0080
Bi-chemotherapy vs Mono-chemotherapy		0.682	[0.496-0.937]
Tri-chemotherapy vs Mono-chemotherapy		0.543	[0.368-0.799]
Lung or liver surgery or radio-frequency	n = 463			< 0.0001
Yes vs No		0.302	[0.235-0.388]

HR: Hazard ratio; CI: Carcinoembryonic antigen; CEA: Carcinoembryonic antigen; LDH: Lactate dehydrogenase; PTR: Primary tumor resection; 5 FU: 5 fluorouracil; EGFR: Epidermal growth factor.